Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Oct 19;22(3):432–440. doi: 10.1016/j.bbmt.2015.10.005

Fig 1. Allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis (MF) patients with prior exposure to JAK1/2 inhibitors.

Fig 1

(A) Probability of overall survival (OS), cumulative incidence of non-relapse mortality (NRM) and cumulative incidence of relapse / progression (CIR). (B) Cumulative incidence of neutrophil count ≥ 0.5x 109 / L and platelet count ≥20 x 109 / L. (C) Cumulative incidence of acute graft versus host disease (GVHD). (D) Cumulative incidence of chronic GVHD